Covering current events in science, the environment, technology and health requires a context and reliable sources that respond quickly.
When science hits the headlines, we publish reactions, explanations, and in-depth analysis from reliable sources, capturing both the evidence and the debates. Our library of science journalism resources and the briefings may be of use to you. Consult our directory of research centres.
We are on the lookout for any controversial information about science (embargoed or not), in order to react with the agility the media needs. Sign up to receive our embargoed contents, all under the Creative Commons licence. Find out more about how we work here.
A study of more than 700,000 people in Sweden analysed the effectiveness of the heterologous schedule, combining the AstraZeneca vaccine with another dose of a messenger RNA vaccine, with the traditional homologous schedule, consisting of two doses of AstraZeneca. The results showed increased protection against SARS-CoV-2 infection when two different vaccines were combined.
The European Medicines Agency issued its recommendations yesterday afternoon regarding the administration of a third dose of the Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) vaccines. These are the reactions of several experts on the matter.
Johnson & Johnson has just released preliminary data from its two-dose trial in a press release. It shows that the second dose increases the antibody response and also confirms the duration of protection among those who received one dose.
With the goal of vaccines reaching a huge part of the European population achieved, we must provide scientific evidence and action to ensure that all people have access to immunisation. We will find herd immunity by vaccinating and monitoring infections now more than ever.